ODI Pharma AB Announces Group Earnings Results for the Third Quarter and Nine Months Ended March 31, 2021
ODI Pharma AB announced Group earnings results for the third quarter and nine months ended March 31, 2021. For the quarter, the Group's net sales amounted to SEK 0 against SEK 1,567 a year ago. The Group's loss after financial items amounted to SEK 41,280 against SEK 1,662,333 a year ago. Loss per share amounted to SEK 0.0031 against SEK 0.11 a year ago.
For the nine months, The Group's net sales amounted to SEK 0 against SEK 218,520 a year ago. The Group's loss after financial items amounted to SEK 2,081,166 against 3,712,338 a year ago. Loss per share amounted to SEK 0.14 against SEK 0.28 a year ago.